Polymer Factory collaborate with University of Massachusetts Amherst

Report this content

Polymer Factory Sweden AB (publ) has signed a material transfer agreement with the University of Massachusetts Amherst (UMass) for transfer of materials from its BowtieD® platform.

Polymer Factory has signed a material transfer agreement with UMass for research incorporating products from Polymer Factory’s BowtieD® platform. The research focus is within oncology and immunotherapy.

CTO Michael Malkoch comments:

“With this agreement secured, renowned researchers from UMass will now have the opportunity to explore Polymer Factory’s dendrimer nanocarrier platform as the most sophisticated dendritic probes on the market, with emphasis on identifying novel design of therapies for patients with troublesome diseases including cancer, diabetes and other immunocompromised conditions.”

Polymer Factory will supply material to UMass to conduct the research. The agreement can potentially lead to new intellectual property for the Company and/or a future supplier role.

About UMass

The University of Massachusetts Amherst is a public research university in Amherst, MA, USA.

For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.

Subscribe

Documents & Links

Quotes

With this agreement secured, renowned researchers from UMass will now have the opportunity to explore Polymer Factory’s dendrimer nanocarrier platform as the most sophisticated dendritic probes on the market, with emphasis on identifying novel design of therapies for patients with troublesome diseases including cancer, diabetes and other immunocompromised conditions.
Michael Malkoch, CTO